February 06 2018

US Securities & Exchange Commission Office of FOIA and Privacy Act Operations 100 F Street, NE Mail Stop 5100 Washington, DC 20549-5100

RECEIVED

FEB 06 2018

Office of FOIA Services

Dear FOIA Office:

Under the Freedom of Information Act (FOIA), please send a copy of the following:

A copy of: Exhibit: 10.27 to the form S-1 filed by Regulus Therapeutics Inc. on August 17, 2012

In the event confidential treatment has not expired provide the specific date for which confidential treatment is still in effect. I do not need a copy of the order. We authorize up to \$61.00 in processing fees. Thank You,

Paul D'Souza

Editor - Deals

Clarivate Analytics Friars House, 160 Blackfriars Road London, UK SE1 8EZ

Phone: +44-2074334789 paul.dsouza@clarivate.com



UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATION PLACE 100 F STREET, NE WASHINGTON, DC 20549-2465

Office of FOIA Services

February 9, 2018

Mr. Paul D'Souza Clarivate Analytics 160 Blackfriars Road London, UK SE1 8EZ

RE: Freedom of Information Act (FOIA), 5 U.S.C. § 552

Request No. 18-02332-E

Dear Mr. D'Souza:

This letter is in response to your request, dated and received in this office on February 6, 2018, for Exhibit 10.27 to the Form S-1, filed by Regulus Therapeutics, Inc. on August 17, 2012.

The Commission extended confidential treatment to Exhibit 10.27 to the Form S-1 under Rule 24b-2 of the Securities and Exchange Act of 1934 through June 22, 2018. Since confidential treatment has been extended, we are providing the expiration date(s) from the relevant CT order(s) as requested.

If you have any questions, please contact me at fultonc@sec.gov or (202) 551-8186. You may also contact me at foiapa@sec.gov or (202) 551-7900. You also have the right to seek assistance from a FOIA Public Liaison, Lizzette Katilius at (202) 551-7900.

Sincerely,

Charlotte Fulton

FOIA Research Specialist